Table of Contents
- Drugs detected in suspected pediatric exposures: a 5-year review.
- FAQ
- How common are cannabis metabolites in pediatric patients presenting with suspected toxic exposures?
- What is the difference in detection rates between immunoassay screening and comprehensive toxicology testing?
- Should cannabis testing be routinely included in pediatric toxicology workups?
- What other substances are commonly detected alongside cannabis in pediatric toxic exposures?
- How should clinicians interpret positive cannabis results in pediatric patients with suspected ingestion?
- Read next
- FAQ
Drugs detected in suspected pediatric exposures: a 5-year review.
Cannabis metabolites were among the most frequently detected substances in pediatric patients presenting with suspected toxic exposures in a 5-year multi-hospital study.
This surveillance study provides contemporary data on the landscape of pediatric toxic exposures, showing cannabis metabolites rank among the most commonly detected substances alongside caffeine, nicotine, and common medications. The finding that comprehensive testing detected substances in 85% of specimens while immunoassays were positive in only 33% demonstrates the limitations of standard screening approaches.
For clinicians managing pediatric exposures, this data informs testing strategies and highlights that cannabis exposure is a frequent consideration in this population. The high detection rate of cannabis metabolites suggests either intentional use in older pediatric patients or unintentional exposure in younger children, both clinically relevant scenarios.
| Study Type | Retrospective Cohort Study |
| Population | Pediatric patients with suspected toxic ingestions at two hospitals, over 6,000 specimens analyzed |
| Intervention | Urine immunoassay screens and comprehensive gas chromatography-mass spectrometry toxicology analysis |
| Comparator | None – descriptive study |
| Primary Outcome | Frequency of drug detection by compound class |
| Key Finding | Cannabis metabolites (carboxy-THC) were among the most frequently detected compounds; cannabinoid immunoassays positive in 33% of specimens |
| Journal | Clinical Toxicology |
| Year | Not specified in abstract |
Cannabis metabolite detection is common in pediatric patients presenting with suspected toxic exposures, warranting consideration in differential diagnosis and testing protocols. Comprehensive toxicology testing reveals substantially more exposures than standard immunoassays alone.
The abstract does not specify patient ages, clinical outcomes, intentional versus unintentional exposures, or the clinical significance of detected substances. It cannot establish whether detected cannabis metabolites caused symptoms or were incidental findings from prior use.
Detection of metabolites does not establish causation for presenting symptoms, and cannabis metabolites can persist long after acute effects resolve. The study design cannot distinguish between recent exposure causing symptoms versus detection of prior use unrelated to the clinical presentation.
Want to apply this research to your care?
CED Clinic translates emerging research into individualized clinical care. Dr. Caplan has treated 30,000+ patients.
Book a consultation →Cannabis metabolites are frequently detected in pediatric toxic exposure cases, reflecting either intentional adolescent use or unintentional pediatric ingestion. Detection requires clinical correlation to determine relevance to the presenting syndrome, and comprehensive testing reveals more exposures than standard screening panels.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
How common are cannabis metabolites in pediatric patients presenting with suspected toxic exposures?
Cannabis metabolites (carboxy-tetrahydrocannabinol) were among the most frequently detected compounds in this 5-year study of over 6,000 pediatric cases. Cannabinoid immunoassays were one of the most commonly positive drug screens, found in 33% of specimens testing positive for drugs of abuse.
What is the difference in detection rates between immunoassay screening and comprehensive toxicology testing?
Drug immunoassays detected substances in 33% of specimens, while comprehensive gas chromatography-mass spectrometry detected drugs in 85% of specimens. This significant difference highlights the superior sensitivity of comprehensive testing methods for identifying toxic exposures in pediatric patients.
Should cannabis testing be routinely included in pediatric toxicology workups?
Yes, given that cannabinoids were among the most frequently positive immunoassays in suspected pediatric exposures. Cannabis testing should be considered as part of standard toxicology screening protocols, especially given changing legal landscapes and increased accessibility of cannabis products.
What other substances are commonly detected alongside cannabis in pediatric toxic exposures?
The most frequently detected compounds included caffeine, nicotine, antihistamines, antipyretics, antidepressants, antipsychotics, and anticonvulsants. This pattern suggests that pediatric exposures often involve multiple household substances and medications rather than isolated cannabis exposure.
How should clinicians interpret positive cannabis results in pediatric patients with suspected ingestion?
Positive cannabis metabolite detection indicates exposure but requires clinical correlation with symptoms and exposure history. Given that carboxy-THC can persist for days to weeks, positive results may not necessarily indicate acute intoxication but rather recent exposure requiring appropriate clinical assessment and intervention.
